
Shares of biotech firm SpringWorks Therapeutics SWTX.O rise 3.2% to $46.13 premarket
Germany's Merck KGaA MRCG.DE has struck a deal to buy co for an equity value of $3.9 billion
Offer price of $47 per share is a premium of 5.1% to last close
But price 22% lower than the about $60 per share analysts expected after a Reuters report on February 10 that the companies were in advanced talks
Transaction will likely close during the second half of 2025, Merck says
Up to last close, SWTX up 23.8% YTD